Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute of the National Institutes of Health
Grant: R01 CA132870
National Cancer Institute of the National Institutes of Health
Grant: U01 CA225427
National Cancer Institute of the National Institutes of Health
Grant: P01 CA210961
National Cancer Institute of the National Institutes of Health
Grant: R01 CA255442
National Cancer Institute of the National Institutes of Health
Grant: R01 CA190299
NCI NIH HHS
Grant: R01 CA227763
National Institutes of Health
Grant: 1P01CA210961-01A1
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
National Institutes of Health
Grant: 1R01CA255442-01
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer
National Institutes of Health
Grant: 5R01CA132870-10
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials
National Institutes of Health
Grant: 5U01CA225427-02
Quantitative Imaging for Assessing Breast Cancer Response to Treatment
National Institutes of Health
Grant: 5R01CA190299-07
Correction of Diffusion Gradient Bias in Quantitative Diffusivity Metrics for MultiPlatform Clinical Oncology Trials
FWCI
2.47
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals